Optimal blood tau species for the detection of Alzheimer's disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study
Laia Montoliu-Gaya,Michael L Alosco,Eukyung Yhang,Yorghos Tripodis,Daniel Sconzo,Madeline Ally,Lana Grötschel,Nicholas J Ashton,Juan Lantero-Rodriguez,Mathias Sauer,Bárbara Gomes,Johanna Nilsson,Gunnar Brinkmalm,Michael A Sugarman,Hugo J Aparicio,Brett Martin,Joseph N Palmisano,Eric G Steinberg,Irene Simkin,Katherine W Turk,Andrew E Budson,Rhoda Au,Lindsay Farrer,Gyungah R Jun,Neil W Kowall,Robert A Stern,Lee E Goldstein,Wei Qiao Qiu,Jesse Mez,Bertrand Russell Huber,Victor E Alvarez,Ann C McKee,Henrik Zetterberg,Johan Gobom,Thor D Stein,Kaj Blennow
DOI: https://doi.org/10.1007/s00401-023-02660-3
2023-12-30
Abstract:Plasma-to-autopsy studies are essential for validation of blood biomarkers and understanding their relation to Alzheimer's disease (AD) pathology. Few such studies have been done on phosphorylated tau (p-tau) and those that exist have made limited or no comparison of the different p-tau variants. This study is the first to use immunoprecipitation mass spectrometry (IP-MS) to compare the accuracy of eight different plasma tau species in predicting autopsy-confirmed AD. The sample included 123 participants (AD = 69, non-AD = 54) from the Boston University Alzheimer's disease Research Center who had an available ante-mortem plasma sample and donated their brain. Plasma samples proximate to death were analyzed by targeted IP-MS for six different tryptic phosphorylated (p-tau-181, 199, 202, 205, 217, 231), and two non-phosphorylated tau (195-205, 212-221) peptides. NIA-Reagan Institute criteria were used for the neuropathological diagnosis of AD. Binary logistic regressions tested the association between each plasma peptide and autopsy-confirmed AD status. Area under the receiver operating curve (AUC) statistics were generated using predicted probabilities from the logistic regression models. Odds Ratio (OR) was used to study associations between the different plasma tau species and CERAD and Braak classifications. All tau species were increased in AD compared to non-AD, but p-tau217, p-tau205 and p-tau231 showed the highest fold-changes. Plasma p-tau217 (AUC = 89.8), p-tau231 (AUC = 83.4), and p-tau205 (AUC = 81.3) all had excellent accuracy in discriminating AD from non-AD brain donors, even among those with CDR < 1). Furthermore, p-tau217, p-tau205 and p-tau231 showed the highest ORs with both CERAD (ORp-tau217 = 15.29, ORp-tau205 = 5.05 and ORp-tau231 = 3.86) and Braak staging (ORp-tau217 = 14.29, ORp-tau205 = 5.27 and ORp-tau231 = 4.02) but presented increased levels at different amyloid and tau stages determined by neuropathological examination. Our findings support plasma p-tau217 as the most promising p-tau species for detecting AD brain pathology. Plasma p-tau231 and p-tau205 may additionally function as markers for different stages of the disease.